ORLANDO -- Vedolizumab (Entyvio) and infliximab (Remicade) led to mostly similar 1-year outcomes in patients with ulcerative colitis previously untreated with a biologic, but the integrin receptor ...

for managing ulcerative colitis include: Anti-TNF agents, such as Humira (adalimumab), Simponi (golimumab), Remicade ...

"Our study suggests that vedolizumab is a viable option for induction and long-term maintenance therapy in children with IBD, particularly in those with ulcerative colitis," the authors concluded.

Entyvio contains the active ingredient vedolizumab. Entyvio is used to treat the signs and symptoms of moderate to severe ulcerative colitis or ... life-threatening if left untreated.